Evidence map›Paper›PMID 41889509›Full record

ArticleFrontiers in medicine2026

Application of oral sulfate solution combined with linaclotide in bowel preparation for colonoscopy.

Haifeng Lan, Mengjie Lu, Shupei Li, Mei Shao, Ya Yang, Qi Zhai, Qing Gao, Yuxiu Liu, Ji Xuan

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Haifeng Lan *Department of Gastroenterology, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China.
Mengjie Lu *Health Science Center, Ningbo University, Ningbo, Zhejiang, China.
Shupei LiDepartment of Gastroenterology, Jinling School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Mei ShaoDepartment of Gastroenterology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Ya YangDepartment of Gastroenterology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Qi ZhaiDepartment of Gastroenterology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Qing GaoDepartment of Gastroenterology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Yuxiu LiuData and Statistics Division of Department of Critical Care Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Ji XuanDepartment of Gastroenterology, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: High-quality bowel preparation is essential for accurate colonoscopy. Currently, linaclotide is used as an adjunctive agent supporting bowel preparation, but evidence for its combination with oral sulfate solution (OSS) remains limited. This study aimed to evaluate whether the addition of linaclotide to OSS could improve the efficacy of bowel preparation. Methods: This single-blind, randomized controlled trial enrolled outpatients scheduled for colonoscopy. Participants were randomly assigned (1:1:1) to one of three groups: the OSS + Linaclotide group, the OSS group, or the polyethylene glycol (PEG) group. The primary outcome was the adequate bowel preparation rate, while secondary outcomes included tolerability, colonoscopy findings, and safety. Efficacy endpoints were assessed in the modified intention-to-treat (mITT) population, and safety was evaluated in the as-treated population. Results: A total of 370 patients were included in the mITT analysis. There was no statistically significant difference in the adequate bowel preparation rate between the OSS + Linaclotide group and the OSS group (86.5% vs. 88.0%; unadjusted relative risk [RR], 0.98; 95% confidence interval [CI], 0.89-1.08; Conclusion: This study did not meet its primary endpoint. Linaclotide added to OSS provided no additional cleansing efficacy over OSS alone or PEG. Exploratory analysis found that the combination may reduce bloating, a potential tolerability advantage requiring further verification in future studies.

Indexed as

bowel preparationcolonoscopylinaclotideoral sulfate solutionPEG

Identifiers

PMID41889509
PMCPMC13014616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.